New Age Alpha Advisors LLC Sells 35,407 Shares of BioMarin Pharmaceutical Inc. $BMRN

New Age Alpha Advisors LLC decreased its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 30.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 79,431 shares of the biotechnology company’s stock after selling 35,407 shares during the period. New Age Alpha Advisors LLC’s holdings in BioMarin Pharmaceutical were worth $4,721,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Activest Wealth Management acquired a new stake in shares of BioMarin Pharmaceutical during the fourth quarter worth approximately $26,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of BioMarin Pharmaceutical during the third quarter worth approximately $40,000. Smartleaf Asset Management LLC increased its holdings in shares of BioMarin Pharmaceutical by 92.5% during the third quarter. Smartleaf Asset Management LLC now owns 749 shares of the biotechnology company’s stock worth $40,000 after buying an additional 360 shares in the last quarter. V Square Quantitative Management LLC acquired a new stake in shares of BioMarin Pharmaceutical during the fourth quarter worth approximately $45,000. Finally, Parallel Advisors LLC increased its holdings in shares of BioMarin Pharmaceutical by 62.2% during the third quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company’s stock worth $42,000 after buying an additional 295 shares in the last quarter. Institutional investors and hedge funds own 98.71% of the company’s stock.

Analysts Set New Price Targets

BMRN has been the subject of several recent analyst reports. Wolfe Research reaffirmed an “outperform” rating on shares of BioMarin Pharmaceutical in a report on Monday, March 16th. Wells Fargo & Company raised their price objective on shares of BioMarin Pharmaceutical from $70.00 to $75.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Weiss Ratings lowered shares of BioMarin Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, May 15th. Wall Street Zen raised shares of BioMarin Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday. Finally, Sanford C. Bernstein lowered their price target on shares of BioMarin Pharmaceutical from $94.00 to $82.00 and set an “outperform” rating for the company in a report on Tuesday, May 5th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $88.67.

Insiders Place Their Bets

In other BioMarin Pharmaceutical news, EVP Charles Greg Guyer sold 16,486 shares of BioMarin Pharmaceutical stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $60.46, for a total transaction of $996,743.56. Following the completion of the sale, the executive vice president owned 79,953 shares of the company’s stock, valued at approximately $4,833,958.38. The trade was a 17.09% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Gregory R. Friberg sold 3,281 shares of BioMarin Pharmaceutical stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $53.85, for a total transaction of $176,681.85. Following the sale, the executive vice president directly owned 51,818 shares of the company’s stock, valued at $2,790,399.30. This represents a 5.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 26,093 shares of company stock valued at $1,555,389 in the last ninety days. Company insiders own 0.85% of the company’s stock.

BioMarin Pharmaceutical Price Performance

BMRN opened at $54.09 on Tuesday. The company has a fifty day moving average price of $54.46 and a two-hundred day moving average price of $56.28. The company has a debt-to-equity ratio of 0.23, a quick ratio of 4.20 and a current ratio of 5.81. BioMarin Pharmaceutical Inc. has a 52 week low of $49.26 and a 52 week high of $66.28. The firm has a market capitalization of $10.45 billion, a PE ratio of 39.48, a P/E/G ratio of 0.41 and a beta of 0.23.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.